Owkin offers three types of AI diagnostic to get drugs to patients faster
Pathologist enhancement
To identify one or multiple biomarkers from IHC or H&E slides
- Solve immediate pharma and care pain points
Biomarker pre-screen
Biomarkers for the early identification of targetable gene alterations (e.g. MSI, KRAS, BRCA/HRD)
- Select efficient targeted drugs, faster
Outcome prediction
Prognostic and predictive AI to predict the course of the disease (e.g. survival, relapse, response to treatment)
- Find the best treatment on time
Owkin's products
First-in-class fast and universally accessible diagnostics
Our products are:
Fast
Faster than genetic tests (minutes vs weeks)
Scalable
Reports at the click of a button
Decentralized
Deployable at all sites
Cost-effective
Cheaper than other modalities
Tissue sparing
Results from routine whole-slide-images
Accelerated
Immediately bring drugs to their target market
Why Owkin?
Strong KOL network (160+) and access to unique data from 60+ leading academic institutions in 12 countries
Development of quality models to tackle real-world medical problems (e.g. Phikon)
Owkin boasts in-house development of digital pathology diagnostics, ISO 13485 & ISO 27001 certified
MSIntuit® CRC
Watch our demo
Learn how MSIntuit®️ CRC pre-screens for Microsatellite Instability directly from digitized H&E slides.
[01:44]